Recombinant Human CD30/TNFRSF8 Fc Chimera (Catalog # 813-CD) under non-reducing conditions only
0.25 µg/106 cells
Measured by its ability to stimulate human IL-6 secretion by HDLM-2 human Hodgkin's lymphoma cells. A Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 272. The ED50 for this effect is typically 0.05 - 0.2 μg/mL.
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Detection of CD30/TNFRSF8 in Jurkat Human Cell Line by Flow Cytometry.
Jurkat human acute T cell leukemia cell line was stained with Mouse Anti-Human CD30/TNFRSF8 Monoclonal Antibody (Catalog # MAB229, filled histogram) or isotype control antibody (Catalog # MAB0041, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.
Human CD30/TNFRSF8 AntibodyEnhances IL-6 Secretion in HDLM-2 Cells.
Human CD30/TNFRSF8Monoclonal Antibody enhances IL-6 secretion in the HDLM-2 human Hodgkin'slymphoma cell line, in a dose-dependent manner, as measured using theQuantikine Human IL-6 ELISA Kit (Catalog #D6050).The ED50for this effect is typically 0.05- 0.2 μg/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 - 6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85-90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).
Kennedy, M.K. et al. (2006) Immunology 118:143.
Tarkowski, M. (2003) Curr. Opin. Hematol. 10:267.
Durkop, H. et al. (1992) Cell 68:421.
Hamann, D. et al. (1996) J. Immunol. 156:1387.
Shanebeck, S.D. et al. (1995) Eur. J. Immunol. 25:2147.
Gruss, H.-J. et al. (1994) Blood 83:2045.
Oflzoglu E. et al. (2009) Adv. Exp. Med. Biol. 647:174.
Del Prete, G. et al. (1995) J. Exp. Med. 182:1655.
Harlin, H. et al. (2002) J. Immunol. 169:2451.
Amakawa, R. et al. (1996) Cell 84:551.
Chiarle, R. et al. (1999) J. Immunol. 163:194.
Vinante, F. et al. (2002) Blood 99:52.
Hansen, H.P. et al. (1995) Int. J. Cancer 63:750.
Hansen, H.P. et al. (2000) J. Immunol. 165:6703.
Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. 32:163.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.